See other companies on Welcome to the Jungle
COTA Healthcare
Database of clinical cancer studies
- 101-200 employees
- Healthcare
- B2B
- Data storage
- Biology
- SaaS
- Data Analysis
- Science
- Financial District, New York, NY
Jump to section
Company mission
Cota's mission is to provide a comprehensive picture of cancer that can be used to advance care and research.
33% employee growth in 12 months
Our take
Founded by a group of doctors, engineers, and data scientists, COTA Healthcare builds solutions for healthcare to analyze, visualize, report, and manage real-world evidence and deliver precision medicine. COTA partners with providers, payers, and life science companies to improve patient outcomes, make clinical sense of claims data, and accelerate drug development.
COTA is now well established, although by no means the only player in the global AI healthcare market, which is expected to reach $39.5 billion by 2026. Competition from larger oncology-focused companies such as Flatiron Health and Tempus means that COTA must keep expanding its oncology database.
The company is now focusing its growth efforts on expanding its oncology real-world data, analytics, and services for its audiences in the years to come. This includes a deep focus on leveraging real-world data to bring equity to cancer care and drug development, by ensuring that its data sets are representative of a diverse population and the epidemiologically relevant population in the US.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- 401k / retirement
- Annual bonus
- Medical / dental / vision benefits
- Monthly commuter benefits
- Stock option grants
- Unlimited paid time off
- Paid sick time – 40 hrs/year
- 11 paid holidays per year
- Paid Parental leave – 8 weeks
- Company team building events
- Educational lunch & learns
- Cause-driven employees
- Employee-led Diversity & Inclusion committee
- Healthy snacks
- Gourmet coffee and cold brew
Company values
- Accountable
- Innovative
- Impactful
- Collaborative
- Excellent
- Fun
Funding (last 2 of 4 rounds)
Nov 2020
$10m
CONVERTIBLE
Feb 2018
$40m
SERIES C
Total funding: $75m
Leadership
Miruna Sasu
(President & CEO)Previous Head of Innovation and Digital Health for Bristol-Myers Squibb, and Head of Clinical Trial Feasibility and Data Science for Johnson & Johnson. Served as Chief Strategy Officer at COTA for 1 year before becoming President & CEO in 2022.